Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Machaon who wrote (15712)	2/23/1998 2:42:00 PM
From: celeryroot.com	Respond to of 32384

Actually, Sparta trades under 1. After skimming over the filings you might want to verify the existence of the patent with relationship to Sparta.

To: Machaon who wrote (15712)	2/23/1998 3:35:00 PM
From: Henry Niman	Respond to of 32384

bob, In addition to 200 issued patents, LGND has about 200 more pending. Yes it is possible for there to be interference. In fact such a situation exists between LGND and Roche over Panretin. LGND has asked for an interference hearing because they filed first (which is the criteria for everywhere but the US In the US, its the discovery date, so lab notebooks usually come into play. I don't think that LGND is worried about Sparta (or Roche, since Ligand scientists discovered 9-cis retinoic acid, which is Panretin).